BioSpace News Archive

Azura Ophthalmics Expands Broad Intellectual Property Portfolio to 12 U.S. and European Patents

Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced the company’s U.S. 11,459,351 patent (the ‘351 patent) was granted by the U.S. Patent and Trademark Office.

October 19, 2022
·
5 min read
Pharm Country

SAVE THE DATE: Eagle Pharmaceuticals to Host Investor Day on Tuesday, December 6, 2022, at the Lotte New York Palace Hotel

Eagle Pharmaceuticals, Inc. announced that the Company will host an Investor Day on Tuesday, December 6, 2022, at the Lotte New York Palace Hotel, at 8:00am ET.

October 19, 2022
·
1 min read
Drug Development

Pivotal Phase 3 Data Showing Significant Improvements in Facial and Total Body Repigmentation with Ruxolitinib Cream (Opzelura™) in Vitiligo Published in New England Journal of Medicine

Incyte (Nasdaq:INCY) today announced that data from the pivotal Phase 3 TRuE-V clinical trial program evaluating ruxolitinib cream (Opzelura™) 1.5% in patients 12 years of age and older with nonsegmental vitiligo have been published in The New England Journal of Medicine (NEJM).

October 19, 2022
·
16 min read
Deals

Prime Medicine Announces Pricing of Upsized Initial Public Offering

Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the pricing of its upsized initial public offering of 10,294,118 shares of its common stock at a price to the public of $17.00 per share.

October 19, 2022
·
4 min read